Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase(R) Grants Stock Options

Accesswire September 21, 2023

Theralase(R) Closes Private Placement Equity Financing

Accesswire September 7, 2023

Theralase Release's 2Q2023 Interim Financial Statements

Accesswire August 29, 2023

Theralase(R) Closes Non-Brokered Private Placement Equity Financing

Accesswire June 30, 2023

Theralase(R) Announces Appointment of New Independent Director

Accesswire June 6, 2023

Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements

Accesswire May 30, 2023

Theralase(R) Releases 1Q2023 Interim Financial Statements

Accesswire May 30, 2023

Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer

Accesswire May 24, 2023

Theralase Provides Update on Phase II Bladder Cancer Study

Accesswire May 10, 2023

Theralase® Releases FY2022 Audited Financial Statements

GlobeNewswire April 26, 2023

Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium

GlobeNewswire February 23, 2023

Anatomy of a Flagship Asset: Theralase Technologies' (TSXV:TLT) Anti-Cancer Therapy

Trevor Abes  February 22, 2023

Theralase® Awarded TSX Venture 50(TM) Recognition as a Top Performing Company

GlobeNewswire February 21, 2023

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

GlobeNewswire February 2, 2023

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

GlobeNewswire January 25, 2023

Theralase ® Announces Warrant Extension

GlobeNewswire January 5, 2023

Theralase Releases Q322 Interim Financial Statements

GlobeNewswire November 29, 2022

Theralase (TSXV:TLT) grants stock options

Brieanna McCutcheon  November 21, 2022

Theralase® Grants Stock Options

GlobeNewswire November 21, 2022

Theralase Technologies (TSXV:TLT) closes private placement

John Ballem  November 18, 2022